Dr. Pineda-Roman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
100 Medical Park Dr
Ste 110
Concord, NC 28025Phone+1 704-403-1370Fax+1 704-403-1389
Summary
- Dr. Mauricio Pineda-Roman is a hematologist in Concord, NC and is affiliated with multiple hospitals in the area, including Atrium Health Cabarrus and Atrium Health's Carolinas Medical Center. He received his medical degree from Universidad del Valle Health Sciences and has been in practice 27 years. He also speaks multiple languages, including Spanish. He specializes in hematologic oncology and is experienced in hematopoietic stem cell transplantation, multiple myeloma, healthcare outcomes research, combined modality therapy, and gene expression profiling. He has more than 40 publications and over 500 citings.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Blood & Bone Marrow Transplant, 2016 - 2017
Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2001 - 2004
Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Residency, Internal Medicine, 1994 - 1998
Universidad del Valle Health SciencesClass of 1990
Certifications & Licensure
CA State Medical License 1996 - Present
NC State Medical License 2017 - 2025
NY State Medical License 2016 - 2018
PA State Medical License 2009 - 2016
AR State Medical License 2004 - 2010
SC State Medical License 2001 - 2005
AZ State Medical License 1997 - 2003- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) Start of enrollment: 2007 Apr 01
Publications & Presentations
PubMed
- MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma.Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry A Paul
Blood Advances. 2024-11-22 - Real-world clinical outcomes with fostamatinib for the treatment of refractory chronic immune thrombocytopenia: a single-center experience.Donald C Moore, Joseph B Elmes, Justin R Arnall, Mauricio Pineda-Roman
Blood Coagulation & Fibrinolysis. 2024-09-01 - Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).Hamid Ehsan, Myra Robinson, Peter M Voorhees, Kristen Cassetta, Shanice Borden
Life. 2024-03-14
Professional Memberships
- Fellow
- Member
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
